Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
In my view Professor Albertsson-Wikland overstates the case for
treating idiopathic short stature with growth hormone. The results overall
are a modest 4cm in adult height with no evidence supplied that this is
actually beneficial either physically or psycologically; the very long
term effects are still unknown yet the potential side-effects of GH are
well known; and the studies may have been confounded by including small-
for-dates babies. He also states that child growth is an integrated marker
of health but does not state whether this applies to normal children. The
latter is the crux of the matter. These children are small but normal.By
definition they do not have a recognisable disease state as most of us
understand it. This 'illness' seems to be wholely defined by statistics
and parental over-expectations. i do not see children with idiopathic high
stature being offered given GH antagonists.
In view of this, I have serious doubts about the ethics of this
"treatment" for a poorly defined "illness".